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Abstract
BACKGROUND: Although shorter telomeres have been associated with Alzheimer’s disease 
(AD), it is unclear whether longitudinal change in telomere length is associated with AD 
progression.
OBJECTIVE: To investigate the association of telomere length change with AD diagnosis and 
progression.
METHODS: In 653 individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
cohort, T/S ratio (telomere vs. single copy gene), a proxy of telomere length, was measured for up 
to five visits per participant (N=1918 samples post-QC) using quantitative PCR (qPCR). T/S ratio 
was adjusted for batch effects and DNA storage time. A mixed effects model was used to evaluate 
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association of telomere length with AD diagnostic group and interaction of age and diagnosis. 
Another mixed effects model was used to compare T/S ratio changes pre- to post-conversion to 
MCI or AD to telomere change in participants with stable diagnoses.
RESULTS: Shorter telomeres were associated with older age (Effect Size (ES)=−0.23) and male 
sex (ES=−0.26). Neither baseline T/S ratio (ES=−0.036) nor T/S ratio change (ES=0.046) differed 
significantly between AD diagnostic groups. MCI/AD converters showed greater, but non-
significant, telomere shortening compared to non-converters (ES=−0.186).
CONCLUSIONS: Although AD compared to controls showed small, non-significant effects for 
baseline T/S ratio and T/S ratio shortening, we did observe a larger, though still non-significant 
effect for greater telomere shortening in converters compared to non-converters. Although our 
results do not support telomere shortening as a robust biomarker of AD progression, further 
investigation in larger samples and for subgroups of participants may be informative.
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INTRODUCTION
Telomeres, chromosomal end caps composed of thousands of hexameric DNA repeats and 
their associated proteins, insulate the ends of the chromosomes from damage and fusion, and 
prevent coding DNA loss during DNA replication [1]. Germline telomere length is heritable, 
influenced by factors including genetic variants, paternal and maternal age, paternal 
telomere length, and paternal birth year [2–8]. Telomere length decreases by 50-100 bp with 
every cell division in vitro [9]; this effect can be offset by the action of telomerase, which 
increases telomere length. Telomeres have been shown to decrease approximately 20-30 bp a 
year in human leukocytes in vivo [10–12]. In addition to genetic factors, telomere length has 
been shown to be influenced by environment and behavior. Many different variables appear 
to associate with somatic telomere length, from stress and diet to drug use and 
environmental pollution [13–22]. Many of these factors are also associated with risk for 
Alzheimer’s disease (AD). Additionally, many different disorders have been reported to be 
associated with shorter or longer telomeres, including disorders which can be comorbid with 
AD and related disorders (ADRD), such as sleep apnea, cardiovascular disease, and diabetes 
[23, 24]. Thus, it appears that many factors associated with shorter telomeres or longitudinal 
telomere shortening have also been associated with ADRD and comorbid disorders, 
suggesting that telomere shortening and cellular pathways potentially activated by genomic 
instability and cellular aging may play a role in mediating environmental/behavioral impact 
on AD risk.
A number of previous studies have provided mixed evidence for the impact of telomere 
length on AD risk [25–29]. A recent, well-powered meta-analysis of 13 of these studies 
(N=2,882) supports an association of shorter telomeres with AD (standardized mean 
difference of −0.984; 95% confidence interval: −1.433 to −0.535; p value<0.001; Effect size 
(ES)=−1.213) [30]. However, interpretation of this effect size is difficult, as there were many 
significant differences between studies included in this analysis including tissue type, 
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measurement method, geographic location, and age. A concern is that several of the included 
studies, including the largest, have much higher median age for AD participants compared to 
controls; it would be difficult to successfully adjust for such a difference when studying 
telomere length, which is intrinsically linked to aging. Furthermore, these studies do not 
indicate whether this association is driven by inherited telomere length, greater telomere 
shortening over time, or a combination of these effects. Studies using Mendelian 
randomization provide support for a causal relationship between shorter telomeres and AD 
[31, 32]. Furthermore, an association of SNPs in telomerase genes with AD risk also 
suggests a role for differential telomere shortening in AD risk [33]. However, to date, the 
contribution of telomere length and telomere longitudinal change to late onset AD risk and 
progression is unclear. Of note, data from related diseases also suggests the potential role of 
telomere shortening in AD risk/progression. Studies of older adults with Down Syndrome 
suggest that telomere shortening may play a role in these adults’ progression to mild 
cognitive impairment (MCI), a prodromal phase of AD [34, 35].
To date, there is a dearth of data on longitudinal telomere length in older cohorts, which has 
not allowed direct investigation of the impact of telomere shortening rate on AD risk and 
progression in older adults. We hypothesized that accelerated telomere shortening would be 
observed in individuals with AD, and that telomere shortening rate may be associated with 
risk for conversion to a more advanced stage of disease (i.e., from normal cognition to MCI 
or MCI to AD).
METHODS
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Data used in the analysis were obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (adni.loni.usc.edu). ADNI, a multi-year public/private 
partnership founded in 2003 by Principal Investigator Michael W. Weiner, at UCSF, is a 
collaboration including the National Institute of Aging (NIA), the National Institute of 
Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration 
(FDA), pharmaceutical companies, and non-profit organizations. This multi-phase ongoing 
longitudinal study includes more than 1800 participants who are cognitively normal (CN), 
have mild cognitive impairment (MCI), or AD, from over 50 sites in the United States and 
Canada. Further information on the ADNI study design, protocols, and diagnostic criteria as 
well as the data and measurements used in these analyses can be found at http://
adni.loni.usc.edu/; the cohort has also been extensively described in numerous publications 
[36–38].
Institutional Review Board approval was obtained by each ADNI site, and informed consent 
was obtained from each study participant or authorized representative. This study was done 
in accord with the ethical standards of the Helsinki Declaration of 1975.
To study telomere length longitudinally in this cohort, a subset of individuals with 
longitudinal DNA samples available were selected who were enriched for conversion from 
CN to MCI or CN/MCI to AD during the study. Each individual had between one and five 
visits with DNA selected for measurement; since the first visit for each individual was not 
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necessarily the baseline visit, and might differ between individuals (i.e., for individual 1, 
visit 1 is baseline, but for individual 2, assayed visit 1 is the twelve month visit), visits are 
referred to as visit 1-5.
Telomere Length Measurement
Telomere length was measured from DNA obtained from blood. Blood was drawn and either 
shipped at room temperature to NCRAD (typically within 1 day) for DNA extraction and 
storage at −80 degrees Celsius, or processed to buffy coats, frozen, then shipped to NCRAD 
for extraction and storage at −80 degrees Celsius. DNA was shipped from NCRAD to the 
Telomere Biology Core Lab (University of California, San Francisco) for telomere length 
measurement via quantitative PCR (qPCR), with a protocol adapted from the published 
original method by Cawthon [39, 40].
Control DNAs were included in each run on each plate and were used to normalize batch 
effects. Every sample was run in triplicate to generate a T/S ratio; this process was repeated 
to obtain another T/S ratio, and these were averaged to obtain the final T/S ratio. When the 
duplicate T/S ratio and the initial ratio varied by more than 7%, the sample was run in 
triplicate a third time and the two closest values were averaged to obtain the final T/S ratio. 
All assays for the entire study were performed using the same lots of reagents. Baseline and 
follow-up samples from the same participant were always measured in the same assay plate 
to control for batch variations. Detailed information about this assay is available in the 
ADNI telomere methods document on LONI (http://adni.loni.usc.edu/), and is also included 
in the Supplemental Methods section (S1) of this report.
T/S Ratio Preprocessing
DNAs used in this assay were plated twice at NCRAD, once for telomere length, and once 
for methylation assays performed independently. The methylation data, which included 59 
SNPs used for quality control, was used to eliminate two of the 1,920 DNA samples as 
potential swaps. Initial quality control identified an instrument calibration bias resulting in 
unequal DNA pipetting. To correct this, we compared the intra-plate coefficient of variation 
(CV) within the triplicate wells in each run for all samples and discarded any second or third 
pipetted well with intra-assay CV>2.5%. The adjusted run data were used to calculate the 
T/S ratios, and inter-assay CV was used to determine the variance between the two 
independently run T/S ratios. Any sample with an inter-assay difference greater than 7% was 
re-run, and the closest two T/S ratios were averaged to obtain the final T/S ratio. The inter-
assay CV for telomere length measurement for the corrected data is 3.0%±3.0%.
Once the additional T/S ratio measurements were integrated into the data set and an 
acceptable inter-assay CV was obtained, calculations were performed with SAS 9.4 software 
to adjust for additional sources of experimental variance. A linear mixed effects model was 
calculated for T/S ratio, including all visits, with plate, row, column, sample type (blood or 
buffy coat), and months of DNA storage between extraction and qPCR as independent 
variables. Repeated effects for replicates nested within participants across time used a 
compound symmetry covariance structure. Results showed that DNA storage and sample 
type (which changed during the course of the study) resulted in longer telomere length in 
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more recently collected samples (i.e. samples from participants at later visits, which we 
would normally expect to be shorter than telomere length measurements from earlier visits) 
Standardized residuals from this model were added to the T/S ratio to obtain an adjusted T/S 
ratio for each DNA sample. Replicates were averaged to obtain one adjusted T/S ratio for 
each participant at each visit. This adjusted, averaged value (hereafter referred to as simply 
T/S ratio) was used for all subsequent analyses.
Statistical Analyses
Statistical analyses were conducted in SAS 9.4. Demographic variables were tested for 
association with AD diagnostic group (CN/MCI/AD) on visit 1 using Pearson Chi-Square 
and analysis of variance (ANOVA) tests as appropriate. These variables included age, sex, 
ethnicity, race, education, Apolipoprotein E (APOE) ε4 carrier status, and smoking (ever 
smoked yes/no).
Mixed effects models were used to determine how AD diagnosis groups (CN/MCI/AD) are 
associated with T/S ratio changes. In the first mixed effects model, diagnostic group is used 
as a time-varying covariate, e.g., an individual who was CN at visit 1-2, then was diagnosed 
MCI at visits 3-4, would have T/S ratio at visit 1-2 in the CN group, and visits 3-4 in the 
MCI group. The mixed effects model accounted for within-subject correlations between 
visits by including a random subject effect. Age at visit, sex, APOE ε4, years of education, 
diagnostic group at visit, and an interaction between age and diagnostic group were included 
in this model. Slope for T/S ratio change over time for each diagnostic group was estimated 
from this model. Effect sizes were derived as the standardized parameter estimates 
representing changes in T/S ratio measured by standard deviations (SD) associated with one 
SD change in the independent variable of interest.
A second mixed effects model was used to determine whether T/S ratio rates of change were 
different between converters and those who remained stable. T/S ratio changes were 
calculated between those obtained at conversion point visit and the visit prior to conversion 
for converters, and between the last two visits for those who remained stable. The model 
included converter status, time interval between preC and postC, sex, APOE ε4, years of 
education, and age at first observation. This mixed effects model allowed for participants to 
be considered for CN converting to MCI or AD and MCI converting to AD (converters with 
disease progression) and multiple conversions from an individual. We chose this method 
with these visits to investigate immediate effects of disease progression on telomere 
shortening rate. Formulae for both mixed effect models are included in Supplemental Mixed 
Effects Model Formulae (S2).
RESULTS
Demographic Variables
Demographic variables by AD diagnostic groups for the N=653 unique individuals with 
telomere data is shown for visit 1 in Table 1. Most individuals in this study are white non-
Hispanic by self-report, with approximately 16 years of education. Of the demographic 
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variables analyzed, APOE ε4 (p<0.001) and older age (p<0.001) were significantly 
associated with AD diagnostic group.
T/S Ratio and AD Diagnosis and Conversion
The results of the first mixed model, including diagnosis at visit and an interaction between 
age and diagnosis, are presented in Table 2. Older age (ES=−0.23, p<0.001) and male sex 
(ES=−0.26, p<0.001) were both significantly associated with smaller T/S ratios (shorter 
telomere length; Figure 1). AD participants had shorter telomeres compared to controls (ES=
−0.036), while MCI participants did not show a significant difference in telomere length 
compared to controls (ES=−0.0087); however, diagnosis was not significantly associated 
with telomere length (p=0.657). The interaction term between age and diagnosis also did not 
reach statistical significance (p=0.6805). As seen in Table 3, controls and MCI 
participantsshowed a similar rate of change (annual change for both groups=−0.005; MCI 
vs. CN ES=−0.001), while AD participants showed a slower rate of telomere shortening 
(annual change=−0.004; AD vs. CN ES=0.046); however, this effect does not reach 
statistical significance (p=0.681). For all three diagnostic groups, annual change in T/S ratio 
showed significant shortening (p<0.001 for all).
Numbers of converters and those with stable disease are show in Table 4, broken into rows 
by participants whose first visit had a CN diagnosis, and those who converted from MCI to 
AD. There were eight individuals who converted twice (CN to MCI to AD) during the 
longitudinal visits included in this study; these individuals’ data were included in the model. 
Longitudinal T/S ratio values are shown for these individuals in Figure 2.
To test whether rate of change differed by disease progression, a second mixed model was 
tested with a term for converter status and results are presented in Table 5. Analysis of 
converters vs. those with stable diagnosis showed an effect of telomere shortening in 
converters compared to those with stable diagnosis (ES=−0.186, p=0.083), with converters 
showing a larger decrease in T/S ratio (mean=−0.023, SE=0.012, p=0.050) preC to postC 
compared to controls and those with stable disease (mean=0.0015, SE=0.0071, p=0.833), 
though this effect does not reach statistical significance.
DISCUSSION
This is the first study to perform a longitudinal investigation of change in telomere length in 
relation to late-onset AD risk and progression. While age and sex showed the expected 
relationship with telomere length, we did not observe a significant association of T/S ratio at 
baseline or significant change in T/S ratio with AD diagnostic group. However, examining 
the effect for AD and MCI compared to controls in the mixed effects model, for AD vs. 
controls telomere length is shorter (ES=−0.036), while for MCI vs. controls telomere length 
shows a negligible difference (ES=−0.0087). This supports the existing literature that AD 
participants have shorter telomeres than controls, though the effect is smaller than the 
estimate by the most recent meta-analysis of telomere length in AD compared to controls 
(ES=−1.213) [30]. However, the much larger effect from the meta-analysis may be partly 
due to inflation, given that some of the studies in the meta-analysis showed a larger age gap 
(AD 7 years older than controls in the largest study); it would be difficult to accurately 
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adjust for such a difference when studying telomeres given that telomere length is known to 
decrease with age. Results from the ADNI cohort also extend these findings to suggest the 
same effect is not observed in individuals with MCI, who have telomere lengths similar to 
controls (difference in T/S ratio=0.0002). In examining the longitudinal rate of telomere 
length change across diagnostic groups, the observation that the AD group showed a 
nonsignificant slower rate of change than controls or MCI was unexpected.
Because this model included all visits with a diagnosis regardless of later disease 
progression, we assessed whether rate of change within diagnostic group, might be 
confounded by different rates of change in individuals who convert compared to those who 
are stable. In a mixed effect model including diagnostic conversion status, we observed 
greater T/S ratio change pre- to post-conversion in converters (ES=−0.186, p=0.08) 
compared to non-converters, though this effect did not reach statistical significance, 
suggesting that in a larger study, AD progression might be significantly associated with a 
greater decrease in T/S ratio.
A number of previous studies have shown mixed evidence for cross-sectional telomere 
length association with AD diagnosis with much of the evidence suggesting that shorter 
telomeres are associated with AD risk [30]. However, these cross-sectional studies were not 
able to investigate the association of rate of change of telomere length with disease risk. This 
is an important point, as a variety of behavioral and environmental variables have been 
shown to play important roles in telomere length change during life, from early life stress to 
diet, exercise, and various pharmaceuticals. Thus, while shorter telomeres at birth are not 
currently a viable target for intervention, the rate of telomere shortening could conceivably 
be modified by behavioral, dietary, or pharmaceutical interventions. Further research is 
needed to confirm the observation of a medium effect for disease progression associated 
with telomere length change, to advance this potentially translatable finding.
The present study has several limitations. Although the lack of statistically significant 
findings may suggest that telomere length is not a key factor in the biological mechanisms 
predisposing to AD, methodological issues and adjustments for experimental variation may 
have reduced the power to detect significant relationships in this dataset. Given that the 
sample type bias and storage time effect had an opposite impact on telomere length 
compared to the normal shortening observed with age, it is possible that some of the signal 
was obscured by this experimental variation. Additionally, the trend for greater telomere 
shortening in converters during the conversion period suggests that this may be a biomarker 
of disease progression. Blood sample collection in ADNI was originally designed to ensure 
an adequate supply of genomic DNA but not to minimize sources of variation for analysis of 
longitudinal changes in DNA. A larger, better-powered study explicitly designed to assess 
longitudinal DNA changes with comparable biospecimen collection and handling at each 
time point is needed to investigate these relationships in greater depth.
Interestingly, while a previous study of healthy post-menopausal older women (N=63) 
showed that APOE ε4 carriers had greater odds of exhibiting enhanced telomere shortening 
over a two year period [41], APOE ε4 carrier status was not significantly associated with 
telomere rate of change in the current analysis. This could be due to other differences in 
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demographic factors between these cohorts including mean age (ADNI mean age is 
approximately a decade older than the cancer study). For the purposes of the current study, 
APOE ε4 was included as a covariate in all analyses due to the known AD risk associated 
with APOE ε4, so this is not likely to have confounded the results.
While large compared to many single site studies of telomere length in AD, the present 
study is smaller than the recent meta-analysis showing shorter telomeres associated with AD 
(N=2,882) [30]. We also show an effect of shorter telomeres in AD, though much smaller 
than the meta-analytic ES (−0.036 vs. −1.213). However, it is possible that we might observe 
this cross-sectional effect reaching statistical significance in a larger cohort. Another 
limitation was that ADNI is a relatively well-educated, homogeneous cohort compared to the 
U.S. population, and excluded individuals with serious mental illnesses. This is an important 
consideration, as there is likely to be more variability in telomere length, and potentially also 
in telomere shortening rate, in a fully representative AD population, since telomere length 
and attrition have been linked to factors including early life stressors, mental illness, drug 
use, and alcoholism [13, 17, 18, 42, 43]. This study was also limited by the lack of suitable 
longitudinal replication data. Future directions should also include obtaining more data to 
perform a well-powered analysis of individuals showing faster disease progression for 
differences in telomere attrition. This analysis did not incorporate genetic data (other than 
APOE) to differentiate between genetic predictors of telomere length and differences in 
length from environmental/behavioral factors, as this was beyond the scope of the current 
work. Analyses of gene/environment interaction in related to telomere length associated 
pathways is however an important future direction. Future studies should also obtain more 
telomere measurements at time intervals prior to preC and following postC visits, to evaluate 
at what point prior to conversion accelerated telomere shortening can be detected, and 
whether telomere shortening accelerates following disease progression. This study was not 
powered to evaluate this measure, as only 1/4 of the converters in the subset of ADNI 
participants selected for this assay had a visit with data prior to the preC visit, and even 
fewer individuals had a visit with data following the postC visit. Previous research in Down 
Syndrome has shown that accelerated telomere shortening is detectable up to 18 months 
prior to diagnosis with MCI in this population [34], suggesting that telomere shortening 
prior to conversion may be a useful biomarker of risk for imminent disease progression.
Another consideration related to study size is the potential influence of drugs on telomere 
length. As pointed out earlier, there are many different genetic, environmental, and 
behavioral variables that have been shown to contribute to telomere length; among these, 
drugs have been shown to influence telomere length and telomerase function [16, 17, 20, 44, 
45]. This is particularly important in the ADNI sample, and other cohorts of older 
individuals, as aging studies and older cohorts tend to be enriched for individuals taking one 
or more drugs on a long-term basis, as well as individuals with more serious medical 
histories who have been exposed to biologically disruptive drugs with drastic systemic 
effects, such as chemotherapy, some of which have a variety of long-term effects. While 
ADNI does not have complete medical records of past and current medication (data based on 
self-report, not medical record), and thus adjusting for drug exposure is beyond the scope of 
the current analysis, future work leveraging cohorts with full electronic health record access 
should consider how drug use may impact telomere length in the AD population.
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It is unclear whether telomere shortening is contributing to the molecular and systemic 
pathways driving AD progression, though this study presents evidence suggesting that 
telomere shortening may accelerate during disease progression. However, the theoretical 
biological underpinnings of this connection are compelling and deserve further investigation. 
Telomere length has been shown to correlate between tissues, suggesting that shortening in 
the periphery may be a marker for shortening telomeres in brain cell populations [26]. 
Telomere shortening in neuronal, microglial or astroglial populations could potentially lead 
to genomic instability and cell death, particularly if, as postulated in several recent papers, 
deficits in neurogenesis may contribute to AD risk [46]. Shorter telomeres in neural stem 
cells could lead to senescence and deficits in neurogenesis, potentially leading to memory 
problems and AD. Additionally, it is possible that telomere shortening could be playing a 
role in increased cellular senescence in the brain. Short telomeres in microglia could 
potentially contribute to senescence-associated secretory phenotype (SASP), leading to 
increased brain inflammation and increasing AD risk. It is also possible the leukocyte 
telomere length is contributing to AD progression via peripheral systemic effects as well. 
Telomere shortening is a marker of cellular aging, suggesting that accelerated cellular aging 
could play a role in AD progression. Telomere shortening in leukocytes could result in 
SASP in these cells as well, increasing chronic inflammation, a known risk factor for AD 
[47]. While this particular marker of cellular aging is novel for AD, the concept of 
accelerated aging as a potential contributor to AD has been around for decades [48]. 
Interestingly, a senescence-accelerated mouse model (SAMP8) has been suggested as a good 
model of late-onset AD, as it exhibits many features observed in early AD, including 
increased oxidative stress and differences in amyloid beta and tau phosphorylation [49]. 
New data have also suggested that telomerase has functions in the cell in addition to 
extending telomeres. Telomerase has been shown to play roles in bolstering Wnt signaling, 
enhancing cell proliferation and/or resistance to apoptosis (an effect that has been shown in 
response to brain injury in mouse brain cells), and promoting DNA damage repair [50–53] 
which are all biological mechanisms that, if reduced or dysfunctional, could theoretically 
contribute to AD as well. Although there is not yet a causal link between telomere 
shortening and AD progression, multiple biological mechanisms that could hypothetically 
underlie this association including effects of senescence and cellular aging in the periphery 
and/or the brain, and effects of reduced telomerase activity.
While previous studies have shown an association of shorter telomere length with AD, this is 
the first study to investigate longitudinal telomere change with AD diagnostic group and 
disease progression. This study shows a non-significant effect of disease progression on 
telomere shortening rate; further study in a larger cohort would be useful to identify the 
mechanism(s) driving this effect. Future studies are needed to investigate the suitability of 
telomere length change as a biomarker, as well as the potential relationship between 
peripheral telomere shortening and measures of AD pathology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. T/S Ratio at Visit 1 by Age and Sex.
T/S ratio at visit 1 is graphed with participant age at visit 1. Each participant is indicated by 
a blue circle or orange triangle, representing female or male, respectively, as shown in the 
key. Blue and orange lines indicate the average linear change in T/S ratio by age for females 
and males, showing that lower T/S ratio is associated with older age, and on average, 
females have longer telomeres than males.
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Figure 2. T/S Ratios across Visits of CN→MCI→AD Converters.
T/S ratios at each visit for the eight individuals included in this study who converted twice 
(CN→MCI→AD) are shown. Each is represented by a different shaded line. Squares 
indicate CN→MCI pre-conversion visit; circles indicate MCI→AD pre-conversion visit.
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Table 1.
Demographics by AD diagnosis at Visit 1 (N=653)
Variables CN (N=223) MCI (N=336) AD (N=94) Total (N=653) p-value
Mean Age (SD) 76.2 (6.7) 72.6 (7.8) 77.0 (8.0) 74.5 (7.7) <0.001
Count (%) Male 112 (50%) 189 (56%) 60 (64%) 361 (55%) 0.074
Count (%) non-Hispanic 219 (98%) 328 (98%) 89 (95%) 636 (97%) 0.090
Count (%) White 216 (97%) 331 (99%) 93 (99%) 640 (98%) 0.204
Mean Education (SD) 16.4 (2.7) 16.2 (2.6) 15.9 (3.1) 16.2 (2.7) 0.380
Count (%) APOE ε4 positivea 58 (26%) 153 (46%) 64 (68%) 275 (42%) <0.001
Count (%) Ever Smoked 92 (41%) 124 (37%) 30 (32%) 246 (38%) 0.268
a
one individual missing APOE ε4 genotype
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Table 2.
Results from Mixed Effects Model on T/S Ratio by AD Diagnosis, Age, Sex, APOE ε4, Years of Education 
and Age and AD Diagnosis Interaction
Variables in Model Parameter Estimate Standard Error p-value
Age at visit −0.005 0.001 <0.001
Male sex −0.044 0.012 <0.001
APOE ε4 carrier 0.014 0.012 0.253
Years of education 0.002 0.002 0.406
Diagnosis at Visit
  AD −0.081 0.126
0.657
  MCI 0.000 0.105
  CN Ref
Interaction between Age and Diagnosis
  AD 0.001 0.002
0.681
  MCI 0.000 0.001
  CN Ref
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Table 3.
Estimated Annual Change in T/S Ratios by AD Diagnosis over All Visits from the Mixed Effects Model in 
Table 2




b −0.005 (−0.007, −0.003) <0.001
MCI 386 / 824 −0.005 (−0.008, −0.003) <0.001
AD 212 / 337 −0.004 (−0.006, −0.002) <0.001
a
p-value tests whether the slope is equal to 0 and comes from mixed effects model on T/S ratio by diagnosis adjusted by age at visit, sex, APOE ε4, 
years of education, and a diagnosis and age interaction
b
Does not include 1 participant with 3 observations since APOE ε4 status was missing and was thus dropped from modeling
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Table 4.
Conversion Status of Participants
Category Converters Stable Diagnosis
CN at visit 1 148 (74.0%) 52 (26.0%)
MCI at any visit* 118 (36.1%) 209 (63.9%)
Total 170 (32.3%) 357 (67.7%)
*
MCI Includes 13 individuals who were CN converters with at least two post-conversion visits, eight of whom subsequently converted to AD
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Table 5.
T/S Ratio Change by Converter* Status







Male Sex 0.021 0.012 0.106
APOE ε4 0.018 0.013 0.182
Age at pre-conversion 0.001 0.001 0.134
Education −0.003 0.002 0.168
Converter vs stable −0.025 0.013 0.083
*
Converters in this model include CN→MCI/AD and MCI→AD
a
PreC T/S ratio is measured at the last pre-conversion visit for the conversion groups; for stable groups, ‘preC’ is the second to last 
(chronologically most recent) visit with T/S ratio data available.
b
PostC T/S ratio is measured at the first post-conversion visit for the conversion groups; for stable groups, ‘postC’ is the most recent visit with T/S 
ratio data available.
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